Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
1,3-1,4-β-D-glucan, also known as mixed-linkage glucan (MLG) or lichenin, is a linear polysaccharide composed of D-glucose units linked by both β-1,3 and β-1,4 glycosidic bonds. It is a major structural component of the cell walls in cereal grains like oats and barley, and it is also found in certain fungi, such as Aspergillus fumigatus, and some bacteria. Biologically, it serves as a dietary fiber that can lower blood cholesterol and regulate glucose levels by increasing the viscosity of intestinal contents and sequestering bile acids. In the context of immunology, it acts as a pathogen-associated molecular pattern (PAMP) recognized by the innate immune system through receptors like Dectin-1 and Complement Receptor 3 (CR3), thereby modulating immune responses. While not a traditional drug target for inhibition, it is a critical diagnostic target (biomarker) for identifying invasive fungal infections and is being explored as a therapeutic immunomodulator in cancer and infectious diseases.
Recognition by pattern recognition receptors (PRRs) to modulate innate immune responses; physical sequestration of bile acids in the gut to lower cholesterol.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 1,3-1,4-β-D-glucan (MLG).